Corporate History
Dimerix Bioscience was established as a private company in 2004, based on the Receptor-Heteromer Investigation Technology (Receptor-HIT). Dimerix Bioscience went through multiple funding rounds through to mid-2014 when financing was secured for the lead program, DMX-200.
Dimerix Bioscience underwent conversion to a public unlisted company in June 2014 and in July 2015 became a wholly owned subsidiary of Sun Biomedical Limited through a reverse takeover. In November 2015, Sun Biomedical’s name was changed to Dimerix Limited, and now trades under the ASX code: DXB.
✨ Support Our Mission ✨
Help us continue building tools that simplify complexity!
Every contribution fuels new features and improvements
Thank you for being part of our journey! 🚀
